# Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation

> **NCT02571062** · PHASE1 · COMPLETED · sponsor: **Drugs for Neglected Diseases** · enrollment: 30 (actual)

## Conditions studied

- Trypanosomiasis, African

## Interventions

- **DRUG:** Fexinidazole

## Key facts

- **NCT ID:** NCT02571062
- **Lead sponsor:** Drugs for Neglected Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02571062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02571062, "Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02571062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*